Products and Platforms
Knopp is advancing dexpramipexole as an immunological therapeutic based on its preclinical and clinical activity in modulating white blood cells known as eosinophils.
Knopp is advancing dexpramipexole as a novel, oral investigational treatment for amyotrophic lateral sclerosis (ALS). ALS is a devastating disease of progressive paralysis with very limited treatment options.
The disruption of cellular bioenergetics has emerged as a common factor in pathways leading to cell death in ALS, Parkinson's, and other neurodegenerative disorders. Knopp is discovering novel small-molecule mediators of these pathways.
Ion channels, or proteins that regulate the excitability of cells, represent an important class of drug targets in several neurological and cardiovascular conditions. Knopp is discovering novel compounds to modulate these channels.
- Calman Prussin, M.D., Joins Knopp Biosciences to Lead Clinical Development of Dexpramipexole in Eosinophilic Asthma January 7, 2016
- Knopp Biosciences Broadens Collaboration with NIH to Investigate Eosinophil-Lowering Effects of Dexpramipexole March 13, 2014
- Knopp Biosciences and NIH to Collaborate in Evaluating Dexpramipexole in Patients with Hypereosinophilic Syndrome January 8, 2014